ClinicalTrials.gg
Not yet recruitingNCT07948447Updated Nov 19, 2026

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO 1306 in Healthy Participants

A Phase 1 interventional study of NEO-1306 and NEO-1306 in IBD (Inflammatory Bowel Disease) and Healthy Adult Participants, sponsored by NeolaiaBio. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by NeolaiaBio · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies in Inflammatory Bowel Diseases with a site in Australia — 12 open to participants now, 14 under way, 3 of them phase 3. Inflammatory Bowel Diseases · Australia.

Planned enrollment
33rd of 50
80 · median 134
Started
2026
with 4 others
Phase 1
8 of 55
3 open now
Primary completion
2027-05
later than 5 of 13 live
Registered
55th of 55
by date

Among the 55 studies in Inflammatory Bowel Diseases with a site in Australia, this one is the 33rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 5 of the 13 other live ones, and was the 55th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

12 of the 55 studies in Inflammatory Bowel Diseases with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 277 Inflammatory Bowel Diseases studies recruiting now, 134 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Inflammatory Bowel Diseases with a site in Australia, or all of them as a file.
02

Study summary

NEO-1306 is being developed for the treatment of moderately to severely active inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). This will be the first study - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO-1306 in Healthy Participants.

03

Conditions studied

  • IBD (Inflammatory Bowel Disease)
  • Healthy Adult Participants
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 65 years (inclusive) at the time of .
  2. In good general health, with no significant medical history, and have no abnormalities on physical examination at Screening and/or before the first administration of IMP.
  3. (BMI) between ≥ 18.0 and ≤ 34.9 kg/m2 and weight ≥ 50 kg.
  4. Nonsmoker and must not have used any tobacco or nicotine-containing products within 2 months prior to Screening.
  5. Clinical laboratory values within normal range at Screening and Day -1, as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee.
  6. Estimated (eGFR) > 80 mL/min/1.73 m² at Screening and Day-1.
  7. Not pregnant or breastfeeding, or willing to cease breastfeeding. Woman of (WOCBP) (agrees to use an acceptable highly effective method from the start of Screening until 90 days after the last dose of IMP or who are abstinent from heterosexual intercourse are not required to use contraception when this is their preferred and usual lifestyle. Male partners of WOCBP must use condom from the start of Screening until 90 days after the last dose of IMP. WOCBP must have a negative pregnancy test at Screening (serum) and Day -1 (urine). Females must agree to not donate ova from the first dose of IMP until at least 90 days after the last dose of IMP or 5 half-lives, whichever is longer.
  8. Women not of childbearing potential (WONCBP) must be for ≥ 12 months (postmenopausal status is to be confirmed through testing of follicle-stimulating hormone [FSH] levels ≥ 40 IU/L at Screening for amenorrhoeic female participants). Women on hormone replacement therapy (HRT) will need to be on stable regimen for at least 3 months before Screening.
  9. Males must be surgically sterile (> 30 days since vasectomy [documented evidence] with no viable sperm before first administration of IMP), or, if engaged in sexual relations with a WOCBP, they must use a condom and either his partner must be surgically sterile (eg, tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy), or an acceptable, highly effective contraceptive method must be used from Screening until 90 days after the last dose of the IMP. Males with same-sex partners (abstinent from penile-vaginal intercourse) or abstinent from heterosexual intercourse are not required to use contraception when this is their preferred and usual lifestyle. Males with WONCBP partners where that partner is the sole sexual partner are not required to use contraception. Males must not donate sperm from the first dose of IMP until at least 90 days after the last dose of IMP or 5 half-lives, whichever is longer.
  10. Informed consent form signed before initiation of any study procedures
  11. Willing and able to comply with all protocol procedures and assessments required for the study.
  12. Has adequate venous access for blood collection.

Exclusion criteria

Exclusion Criteria:

  1. Underlying physical or psychological medical condition that, in the opinion of the PI or designee, would make the participant unlikely to comply with the protocol or complete the study per protocol.
  2. Blood, plasma or donation or had significant blood loss (> 500 mL) within 30 days prior to the first administration of IMP.
  3. Fever (tympanic temperature > 37.7°C) or symptomatic viral or bacterial infection within 1 week prior to Screening.
  4. Dysphagia that would limit ability to swallow IMP.
  5. Positive test for virus (HCV), surface antigen (HBsAg), (HIV) types 1 and 2 antibody at Screening.
  6. Vaccination with a within 4 weeks prior to the first administration of IMP, during the study and 2 weeks post last administration of IMP. Vaccination with non-live vaccinations is not allowed for the duration of study.
  7. History of life-threatening infection (eg, meningitis) that in the opinion of PI may increase the risk to the participant or interfere with study assessments.
  8. History of , except for non-melanoma skin cancer, excised more than 2 years ago and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to Screening.
  9. History of severe allergic or anaphylactic reactions, or sensitivity to the IMP or its constituents.
  10. Cardiovascular disease including heart failure with reduced , atrial fibrillation requiring anticoagulation, or any other cardiovascular illness that, in the opinion of the PI, warrants exclusion from the study.
  11. History of hospitalisation or major surgery within 6 months prior to Screening.
  12. Infections requiring parenteral antibiotics within 6 months prior to Screening.
  13. Abnormal mean triplicate findings at Screening, and Day -1 that are considered by the PI or designee to be
  14. Unstable vital sign(s) or the following values seen at Screening, Day -1 or on Day 1 following 5 minutes of resting in the supine position
  15. Positive toxicology Screening panel (urine test including qualitative identification of methamphetamines, opiates, cocaine, cannabinoid [THC], phencyclidine, benzodiazepines, barbiturates, methadone, tricyclic antidepressants, amphetamines.), positive alcohol breath test at Screening or Day -1; positive cotinine screen test at Day -1.
  16. History of substance abuse or dependency or history of recreational intravenous (IV) drug use over the last 5 years (by self-declaration).
  17. Regular alcohol consumption defined as > 10 standard drinks per week (where 1 standard drink = 360 mL of beer, 45 mL of 40% spirit or a 150 mL glass of wine) or > 4 standard drinks on any single day.
  18. Unwilling to abstain from alcohol and nicotine-containing products (eg, cigar, cigarettes, vapes) from 72 hours prior to admission to the study site until discharge from study site and from 24 hours prior to any follow-up visits.
  19. Use of any medical device or investigational drug within 30 days or 5 half lives of the investigational drug (whichever is longer) prior to the Screening.
  20. Use of any prescription drugs (other than regular like hormonal contraception; oral contraceptive pills, long-acting implantable hormones, injectable hormones, a vaginal ring, or an intrauterine device [IUD]), over-the-counter medication, herbal remedies, supplements or vitamins within 14 days prior to the first administration of IMP or anticipated use during the course of the study without prior approval of the PI and MM. Simple analgesia (paracetamol, nonsteroidal anti-inflammatory drug [NSAID]) may be permitted at the discretion of the PI.
  21. Use of any NAD modulating supplements
  22. Anything that the PI considers would jeopardise the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    SAD Cohort A1

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    SAD Cohort A2

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    SAD Cohort A3

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    SAD Cohort A4

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    SAD Cohort A5

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    SAD Cohort A6

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    MAD Cohort B1

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    MAD Cohort B2

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    MAD Cohort B3

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Experimental
    MAD Cohort B4

    Drug: NEO-1306 · Drug: NEO-1306 Placebo

  • Placebo comparator
    SAD Placebo

    Drug: NEO-1306

  • Placebo comparator
    MAD Placebo

    Drug: NEO-1306

Interventions

  • DrugNEO-1306

    NEO-1306, single Dose #1

  • DrugNEO-1306

    NEO-1306, single Dose #2

  • DrugNEO-1306

    NEO-1306, single Dose #3

  • DrugNEO-1306

    NEO-1306, single Dose #4

  • DrugNEO-1306

    NEO-1306, single Dose #5

  • DrugNEO-1306

    NEO-1306, single Dose #6

  • DrugNEO-1306

    NEO-1306, Multiple Dose #1, single dose once per day for 14 days

  • DrugNEO-1306

    NEO-1306, Multiple Dose #2, single dose once per day for 14 days

  • DrugNEO-1306

    NEO-1306, Multiple Dose #3, single dose once per day for 14 days

  • DrugNEO-1306

    NEO-1306, Multiple Dose #4, single dose once per day for 14 days

  • DrugNEO-1306 Placebo

    SAD Placebo

  • DrugNEO-1306 Placebo

    MAD Placebo

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v6.0

    Time frame: 7 days for SAD and 25 days for MAD

Secondary outcomes

  1. To characterize the maximum plasma concentration (Cmax) of NEO-1306

    Time frame: 7 days for SAD and 25 days for MAD

  2. To characterize the time to maximum plasma concentration (Tmax) of NEO-1306

    Time frame: 7 days for SAD and 25 days for MAD

  3. To characterize the terminal elimination half life (t 1/2) of NEO-1306

    Time frame: 7 days for SAD and 25 days for MAD

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No plan to share IPD; summary results will be posted on ClinicalTrials.gov and published.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 5 months is below that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 19, 2026
StartEst.
Dec 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948447
Lead sponsor
NeolaiaBio
Collaborators
NeolaiaBio Aus Pty Ltd
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Hannah Kovacs
Contact
hannah.kovacs@cmax.com.au
+61 (0)405 866 911
Development Head
study director · NeolaiaBio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion